Steroid therapy down

At baseline, 8 patients were on steroid therapy, with a mean dose of 15.7 mg/day. At month 6, only 1 patient was still on steroids (at 2 mg/day).

The group will continue to monitor patients during a PRN phase “to examine the long-term benefits of the study,” he added.

Dr. Sepah noted that active disease was defined as vitreous haze of 1+, so only those with edema and haze were evaluated-as such, the study was not designed to evaluate those with very low or nonexistent haze.

“If there are patients with macular edema alone, the edema will decrease,” Dr. Sepah said. “Because in all the patients who had macular edema, irrespective of what the haze score was, we did see a decrease, a significant improvement in the CRT. They will definitely show an improvement.”

Yasir Jamal Sepah, MBBS

E: [email protected]

This article was adapted from a presentation Dr. Sepah delivered at the 2016 American Academy of Ophthalmology meetng. Dr. Sepah is a consultant for Genentech.